-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Oppenheimer Lowers Nkarta (NASDAQ:NKTX) to Market Perform
Oppenheimer Lowers Nkarta (NASDAQ:NKTX) to Market Perform
Oppenheimer lowered shares of Nkarta (NASDAQ:NKTX – Get Rating) from an outperform rating to a market perform rating in a research note published on Thursday, Marketbeat.com reports.
A number of other research firms have also recently commented on NKTX. Mizuho cut their target price on shares of Nkarta from $81.00 to $26.00 and set a buy rating for the company in a research note on Wednesday, November 16th. Cantor Fitzgerald reissued an overweight rating on shares of Nkarta in a research note on Wednesday, September 21st. Canaccord Genuity Group started coverage on shares of Nkarta in a research note on Monday, October 10th. They set a buy rating and a $25.00 target price for the company. Finally, Canaccord Genuity Group began coverage on shares of Nkarta in a research note on Monday, October 10th. They set a buy rating and a $25.00 target price for the company. One investment analyst has rated the stock with a hold rating and nine have issued a buy rating to the company. According to MarketBeat, the company has an average rating of Moderate Buy and a consensus price target of $29.90.
Get Nkarta alerts:Nkarta Stock Performance
NKTX opened at $5.54 on Thursday. The stock has a market capitalization of $270.43 million, a price-to-earnings ratio of -2.07 and a beta of -0.06. The company has a fifty day moving average of $9.73 and a two-hundred day moving average of $12.44. Nkarta has a fifty-two week low of $5.22 and a fifty-two week high of $20.35.
Insider Buying and Selling at Nkarta
In other Nkarta news, CEO Paul J. Hastings sold 23,376 shares of the business's stock in a transaction dated Wednesday, September 28th. The shares were sold at an average price of $13.03, for a total value of $304,589.28. Following the transaction, the chief executive officer now directly owns 250,959 shares in the company, valued at approximately $3,269,995.77. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 5.60% of the stock is currently owned by company insiders.Hedge Funds Weigh In On Nkarta
Several institutional investors and hedge funds have recently bought and sold shares of NKTX. Federated Hermes Inc. boosted its holdings in Nkarta by 735.3% in the 1st quarter. Federated Hermes Inc. now owns 4,711 shares of the company's stock valued at $54,000 after purchasing an additional 4,147 shares during the last quarter. Wasatch Advisors Inc. boosted its holdings in Nkarta by 33.4% in the 1st quarter. Wasatch Advisors Inc. now owns 842,302 shares of the company's stock valued at $9,585,000 after purchasing an additional 210,700 shares during the last quarter. Renaissance Technologies LLC lifted its holdings in shares of Nkarta by 69.7% in the 1st quarter. Renaissance Technologies LLC now owns 234,000 shares of the company's stock worth $2,663,000 after acquiring an additional 96,100 shares during the last quarter. State Street Corp lifted its holdings in shares of Nkarta by 1.0% in the 1st quarter. State Street Corp now owns 276,318 shares of the company's stock worth $3,144,000 after acquiring an additional 2,806 shares during the last quarter. Finally, Deep Track Capital LP lifted its holdings in shares of Nkarta by 67.2% in the 1st quarter. Deep Track Capital LP now owns 2,113,795 shares of the company's stock worth $24,055,000 after acquiring an additional 849,369 shares during the last quarter. 87.22% of the stock is currently owned by institutional investors and hedge funds.
About Nkarta
(Get Rating)
Nkarta, Inc, a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells.
See Also
- Get a free copy of the StockNews.com research report on Nkarta (NKTX)
- MarketBeat: Week in Review 12/19 – 12/23
- These Steelmakers Deserve A Place On Your 2023 Watch List
- Inflation Cools, Where Does The S&P 500 Go Now
- Cintas Beats Inflation With Operating Leverage
- Your Decision to Buy Palantir May Simply Be a Matter of Time
Receive News & Ratings for Nkarta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nkarta and related companies with MarketBeat.com's FREE daily email newsletter.
Oppenheimer lowered shares of Nkarta (NASDAQ:NKTX – Get Rating) from an outperform rating to a market perform rating in a research note published on Thursday, Marketbeat.com reports.
據Marketbeat.com報道,在週四發佈的一份研究報告中,奧本海默將恩卡塔(納斯達克代碼:NKTX-GET Rating)的股票評級從表現優於大盤下調至市場表現。
A number of other research firms have also recently commented on NKTX. Mizuho cut their target price on shares of Nkarta from $81.00 to $26.00 and set a buy rating for the company in a research note on Wednesday, November 16th. Cantor Fitzgerald reissued an overweight rating on shares of Nkarta in a research note on Wednesday, September 21st. Canaccord Genuity Group started coverage on shares of Nkarta in a research note on Monday, October 10th. They set a buy rating and a $25.00 target price for the company. Finally, Canaccord Genuity Group began coverage on shares of Nkarta in a research note on Monday, October 10th. They set a buy rating and a $25.00 target price for the company. One investment analyst has rated the stock with a hold rating and nine have issued a buy rating to the company. According to MarketBeat, the company has an average rating of Moderate Buy and a consensus price target of $29.90.
其他一些研究公司最近也對NKTX發表了評論。瑞穗在11月16日週三的一份研究報告中將Nkarta的股票目標價從81.00美元下調至26.00美元,並為該公司設定了買入評級。康託·菲茨傑拉德在9月21日星期三的一份研究報告中重新發布了對Nkarta股票的增持評級。Canaccel Genuity Group在10月10日星期一的一份研究報告中開始對Nkarta的股票進行報道。他們為該公司設定了買入評級和25.00美元的目標價。最後,Canaccel Genuity Group在10月10日星期一的一份研究報告中開始報道Nkarta的股票。他們為該公司設定了買入評級和25.00美元的目標價。一名投資分析師對該股的評級為持有,9名分析師對該公司的評級為買入。根據MarketBeat的數據,該公司的平均評級為中等買入,共識目標價為29.90美元。
Nkarta Stock Performance
Nkarta股票表現
NKTX opened at $5.54 on Thursday. The stock has a market capitalization of $270.43 million, a price-to-earnings ratio of -2.07 and a beta of -0.06. The company has a fifty day moving average of $9.73 and a two-hundred day moving average of $12.44. Nkarta has a fifty-two week low of $5.22 and a fifty-two week high of $20.35.
NKTX週四開盤報5.54美元。該股市值為2.7043億美元,本益比為-2.07倍,貝塔係數為-0.06。該公司的50日移動均線切入位在9.73美元,200日移動均線切入位在12.44美元。Nkarta的52周低點為5.22美元,52周高位為20.35美元。
Insider Buying and Selling at Nkarta
恩卡爾塔的內幕買賣
Hedge Funds Weigh In On Nkarta
對沖基金對Nkarta進行加碼
Several institutional investors and hedge funds have recently bought and sold shares of NKTX. Federated Hermes Inc. boosted its holdings in Nkarta by 735.3% in the 1st quarter. Federated Hermes Inc. now owns 4,711 shares of the company's stock valued at $54,000 after purchasing an additional 4,147 shares during the last quarter. Wasatch Advisors Inc. boosted its holdings in Nkarta by 33.4% in the 1st quarter. Wasatch Advisors Inc. now owns 842,302 shares of the company's stock valued at $9,585,000 after purchasing an additional 210,700 shares during the last quarter. Renaissance Technologies LLC lifted its holdings in shares of Nkarta by 69.7% in the 1st quarter. Renaissance Technologies LLC now owns 234,000 shares of the company's stock worth $2,663,000 after acquiring an additional 96,100 shares during the last quarter. State Street Corp lifted its holdings in shares of Nkarta by 1.0% in the 1st quarter. State Street Corp now owns 276,318 shares of the company's stock worth $3,144,000 after acquiring an additional 2,806 shares during the last quarter. Finally, Deep Track Capital LP lifted its holdings in shares of Nkarta by 67.2% in the 1st quarter. Deep Track Capital LP now owns 2,113,795 shares of the company's stock worth $24,055,000 after acquiring an additional 849,369 shares during the last quarter. 87.22% of the stock is currently owned by institutional investors and hedge funds.
幾家機構投資者和對沖基金最近買賣了NKTX的股票。聯合愛馬仕公司在第一季度增持了735.3%的恩卡爾塔股份。聯合愛馬仕公司現在擁有4,711股該公司股票,價值54,000美元,在上個季度又購買了4,147股。Wasatch Advisors Inc.在第一季度將其在Nkarta的持股增加了33.4%。Wasatch Advisors Inc.在上個季度額外購買了210,700股票後,現在擁有842,302股該公司股票,價值9,585,000美元。復興科技有限責任公司在第一季度增持了69.7%的Nkarta股票。復興科技有限責任公司在上個季度增持了96,100股後,目前持有該公司23.4萬股股票,價值2,663,000美元。道富銀行在第一季度增持了1.0%的Nkarta股票。道富銀行目前持有276,318股該公司股票,價值3,144,000美元,此前該公司在上個季度又收購了2,806股。最後,Deep Track Capital LP在第一季度增持了67.2%的Nkarta股票。Deep Track Capital LP在上個季度額外收購了849,369股後,現在擁有2,113,795股該公司股票,價值24,055,000美元。87.22%的股票目前由機構投資者和對沖基金持有。
About Nkarta
關於恩卡爾塔
(Get Rating)
(獲取評級)
Nkarta, Inc, a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells.
Nkarta,Inc.是一家臨床階段的生物製藥公司,開發和商業化癌症治療的細胞療法。該公司的細胞免疫療法涉及自然殺傷(NK)細胞表面的嵌合抗原受體,使細胞能夠識別腫瘤細胞表面存在的特定蛋白質或抗原。
See Also
另請參閱
- Get a free copy of the StockNews.com research report on Nkarta (NKTX)
- MarketBeat: Week in Review 12/19 – 12/23
- These Steelmakers Deserve A Place On Your 2023 Watch List
- Inflation Cools, Where Does The S&P 500 Go Now
- Cintas Beats Inflation With Operating Leverage
- Your Decision to Buy Palantir May Simply Be a Matter of Time
- 免費獲取StockNews.com關於NKTX的研究報告
- MarketBeat:回顧一週12/19-12/23
- 這些鋼鐵制造商理應在2023年觀察名單上佔有一席之地
- 通脹降溫,標普500指數何去何從
- Cintas以經營槓桿擊敗通脹
- 你買下Palantir的決定可能只是個時間問題
Receive News & Ratings for Nkarta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nkarta and related companies with MarketBeat.com's FREE daily email newsletter.
接受《Nkarta Daily》的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Nkarta和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧